PHILA

NCT03863223 📎

Regimen

Experimental
Pyrotinib 400 mg PO daily + trastuzumab + docetaxel.
Control
Placebo + trastuzumab + docetaxel.

Population

HER2-positive untreated metastatic or recurrent breast cancer, Chinese patients, first-line setting.

Key finding

PHILA established pyrotinib + trastuzumab + docetaxel as a Chinese-developed 1L option for HER2+ MBC. NMPA approved 2023; CSCO guideline incorporated. Adds a TKI-based alternative to the pertuzumab-based standard in China.

Source: PMID 37907210

Timeline

  • Publication: 2023 Oct 31

Guideline citations

  • NCCN BREAST